Clinical Trial Update: Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating single and repeated intravitreal doses of ICON-1 in patients with uveal melanoma; study completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroid Neoplasm
• Uveal Melanoma

Drugs mentioned

• ICON-1

Snippet

Sponsor: Iconic Therapeutics, Inc. | Conditions: Uveal Melanoma, Choroid Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2020-09-14